Clay Siegall Aims to Make a Leading Pharma Out of Seattle Genetics
Seattle Genetics has a sculpture that models the human antibody. Seattle Genetics centers on the study, manipulation, and packaging of antibodies into drugs since its foundation in 1998. The company’s antibodies can connect to therapies hence target cancer cells through the delivery of toxic payloads which destroy the cells from the inside. The technique raises the potential of the firm to be highly competitive in the industry.
Seattle Genetics prides itself on having an approximate market value of 10 billion dollars and employing 900 professionals. The company is the leading biotech in Washington. The institution invests in marketing and research. The company expects to increase its staff by 200 during 2017.
Seattle Genetics has Adcetris as its flagship product. Adcetris finds application in the treatment of Hodgkin lymphoma. The company expects the sales of the drug to take off if the clinical tests come out positive.
The company’s head and co-founder, Clay Siegall, said that Seattle Genetics is a multiproduct and an upcoming oncology organization. The president expressed his desire to create a massive company when he pointed out the multiple products in the company’s pipeline. He maintained that he did not desire to sell the business to larger firms as is almost the norm with many biotech companies. He said he would make the company turn into a big pharma. Clay Siegall expresses his ambitions in his commitment to shifting the company’s focus on drug development to managing all the complexities of marketing internationally. Dr. Siegall opened his Switzerland office that could allow Seattle to handle its global marketing.
Siegall’s company has a steep trajectory of growth. The company’s stock price keeps on rising alongside the sales. The company’s valuation also is increasing and reflects the firm’s investment in research and future buyout. Siegall keeps working against terrible odds and still manages to be a successful entrepreneur.
Dr. Clay Siegall is the president and CEO of the company he co-founded in 1998, Seattle Genetics. Through his leadership, the company continues to build an array of antibody-based therapies for cancer. Dr. Siegall aided the company in raising over 675 million dollars during the company’s capital-generating activities.
Dr. Siegall graduated with an undergraduate degree in Zoology from Maryland University and got awarded a Ph.D. in Genetics from the George Washington University. From 1988 till 1991, Dr. Siegall worked with the National Institutes of Health and later joined Bristol-Myers Institute to 1997. He then co-founded Seattle Genetics in 1998. Dr. Clay continues to be a proven leader in the biopharmaceutical field.